Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Scott who wrote (1450)	1/22/1998 12:15:00 PM
From: Pseudo Biologist	Respond to of 1762

Scott, you are welcome. By the way, a reimbursement dialog has emerged over the last couple of days in the Biogen thread. Feel free to drop by and set us straight in case we are getting too paranoid on this. One of the participants is a practicing neurologist who prescribes Avonex to his patients; he must have some interesting insight on the issues. BTW-2, Genentech/IDEC sold $5.5 mill worth of Rituxan over the Dec 17-31 period. Off-label or not this looks pretty good, although it is certainly too early to tell, or extrapolate, anything from this one data point. PB